Voluntary transparency regarding the supply of antiviral agents for the treatment of Covid-19 patients ex post
The National Institute for Public Health and the Environment (RIVM) intends to supply 5,000 antiviral treatments for Covid-19 patients via a negotiated procedure without prior publication. The contract is aimed at obtaining medicinal products that comply with Dutch and European regulations regarding quality, safety, and traceability. The emphasis lies on voluntary transparency after delivery, allowing the public and medical community to gain insight into the agents used, the pricing, and the logistics chain. The procedure has not been published, but the RIVM indicates that the results and the criteria used will be made available upon completion. The procurement is a standard supply contract without additional services, but requires a careful selection of a supplier with experience in handling large quantities of antiviral agents and who can meet strict delivery and quality standards.
Supplies · Onderhandeling zonder bekendmaking · European procedure
01What is being requested
The National Institute for Public Health and the Environment (RIVM) intends to supply 5,000 antiviral treatments for Covid-19 patients via a negotiated procedure without prior publication. The contract is aimed at obtaining medicinal products that comply with Dutch and European regulations regarding quality, safety, and traceability. The emphasis lies on voluntary transparency after delivery, allowing the public and medical community to gain insight into the agents used, the pricing, and the logistics chain. The procedure has not been published, but the RIVM indicates that the results and the criteria used will be made available upon completion. The procurement is a standard supply contract without additional services, but requires a careful selection of a supplier with experience in handling large quantities of antiviral agents and who can meet strict delivery and quality standards.
Supply of 5,000 antiviral agent treatments for the treatment of Covid-19 patients.
02Outcome
Merck Sharp & Dohme
03Exclusion grounds
- No specific exclusion grounds were extracted. In a European tender, the mandatory and discretionary grounds of art. 2.86/2.87 of the Dutch Procurement Act almost always apply — check the European Single Procurement Document (ESPD).
04Value in context
The contracting authority did not publish an estimated value — common for a large share of contracts. The EU threshold for leveringen is € 221.000, for reference.
05Bidders in this segment
06Legal themes that may be relevant here
07Frequently asked questions
What is the scope of the supply of antiviral agents?
What information will be made transparent after the completion of the contract?
Automatically compiled from the official tender data and documents.
08Estimated value versus the market
€ 317K
€ 892K
€ 3,3 mln
Gegunde waarden in CPV 33 · leveringen n=528